Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
about
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.The Role of Galectins as Modulators of Metabolism and Inflammation.
P2860
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@en
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@nl
type
label
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@en
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@nl
prefLabel
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@en
Combined Anti-VEGF and Anti-CT ...... h Favorable Clinical Outcomes.
@nl
P2093
P2860
P1476
Combined Anti-VEGF and Anti-CT ...... th Favorable Clinical Outcomes
@en
P2093
Anita Giobbie-Hurder
David McDermott
Donald Lawrence
Erin M Connolly
F Stephen Hodi
George Murphy
Glenn Dranoff
Jing Ouyang
Jingjing Li
P2860
P304
P356
10.1158/2326-6066.CIR-16-0385
P577
2017-05-04T00:00:00Z